Pain in Parkinson's Disease With Motor Fluctuations.
NCT03648671 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 48
Last updated 2018-08-27
Summary
Pain (spontaneous pain) is a fundamental non-motor symptom (NMS) of Parkinson's disease (PD) that is prevalent throughout the condition and often unrecognized and undertreated. The study of the scalp laser-evoked potentials (LEPs) (evoked pain) allows a non-invasive exploration of pain central pathways in humans. This technique proved useful in elucidating the physiopathology underlying different pain syndromes. This study has been conceived to study spontaneous pain (and/or evoked pain by laser stimulation) in PD patients (with or without pain) with motor fluctuations under drugs-on (Safinamide Metansolfonato or Rasagilina Mesilato).
Conditions
- Parkinson Disease
Interventions
- DRUG
-
safinamide metansolfonato (12 weeks)
safinamide metansolfonato
- DRUG
-
safinamide metansolfonato (12 weeks)
safinamide metansolfonato
- DRUG
-
rasagilina mesilato (12 weeks)
rasagilina mesilato
- DRUG
-
rasagilina mesilato (12 weeks)
rasagilina mesilato
Sponsors & Collaborators
-
Azienda Ospedaliera Universitaria Integrata Verona
collaborator OTHER -
Universita di Verona
lead OTHER
Principal Investigators
-
Michele Tinazzi, MD, PhD · Azienda Ospedaliera Universitaria Integrata Verona
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-03-28
- Primary Completion
- 2019-03-28
- Completion
- 2019-11-30
Countries
- Italy
Study Locations
More Related Trials
-
The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease
NCT00032812 ·Status: COMPLETED
-
An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD
NCT03994328 ·Status: COMPLETED
-
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
NCT00286897 ·Status: COMPLETED ·Phase: PHASE3
-
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
NCT02565628 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
NCT02469090 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
NCT02197130 ·Status: COMPLETED ·Phase: PHASE2
-
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
NCT00627640 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
NCT01026428 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
NCT03881371 ·Status: COMPLETED ·Phase: PHASE3
-
Non Motors Aspects in De Novo Parkinson's Disease
NCT02786667 ·Status: UNKNOWN ·Phase: PHASE3
-
Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease
NCT00921128 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
NCT03922711 ·Status: TERMINATED ·Phase: PHASE2
-
Impact of Pharmaceutical Care on Drug-related Problems in Patients With Parkinson's Disease
NCT05410210 ·Status: COMPLETED ·Phase: NA
-
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
NCT03987750 ·Status: WITHDRAWN ·Phase: PHASE3
-
Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease
NCT02601586 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
NCT02373072 ·Status: COMPLETED ·Phase: PHASE1
-
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
NCT05766813 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
NCT00203164 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa
NCT00582673 ·Status: COMPLETED ·Phase: PHASE2
-
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
NCT01215227 ·Status: TERMINATED ·Phase: PHASE3
-
Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa
NCT00244387 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.
NCT05924243 ·Status: COMPLETED ·Phase: PHASE1
-
18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
NCT01286935 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations
NCT00451633 ·Status: WITHDRAWN ·Phase: PHASE2
-
PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
NCT03665454 ·Status: COMPLETED ·Phase: PHASE1